Zacks Company Profile for SAB Biotherapeutics, Inc. (SABS : NSDQ) |
|
|
|
Company Description |
SAB Biotherapeutics Inc. is a clinical-stage biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies. It produces natural, specifically targeted, high-potency, human polyclonal immunotherapies. SAB Biotherapeutics Inc., formerly known as Big Cypress Acquisition Corp., is based in SIOUX FALLS, S.D.
Number of Employees: 139 |
|
|
|
Price / Volume Information |
Yesterday's Closing Price: $1.94 |
Daily Weekly Monthly
 |
20 Day Moving Average: 59,646 shares |
Shares Outstanding: 42.96 (millions) |
Market Capitalization: $83.35 (millions) |
Beta: 0.56 |
52 Week High: $12.90 |
52 Week Low: $1.61 |
Short Interest Ratio: |
|
% Price Change |
% Price Change Relative to S&P 500 |
4 Week |
-25.67% |
-18.56% |
12 Week |
-61.12% |
-57.82% |
Year To Date |
-75.16% |
-70.46% |
|
|
|
|
|
|
|
General Corporate Information |
Officers
Eddie J. Sullivan - Chief Executive Officer
Samuel J. Reich - Executive Chairman
Kipp Erickson - Chief Operating Officer
Russell P. Beyer - Chief Financial Officer
Jeffrey G. Spragens - Director
|
|
Peer Information
SAB Biotherapeutics, Inc. (CORR.)
SAB Biotherapeutics, Inc. (RSPI)
SAB Biotherapeutics, Inc. (CGXP)
SAB Biotherapeutics, Inc. (BGEN)
SAB Biotherapeutics, Inc. (GTBP)
SAB Biotherapeutics, Inc. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 78397T103
SIC: 2836
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/11/22
|
|
Share - Related Items
Shares Outstanding: 42.96
Most Recent Split Date: (:1)
Beta: 0.56
Market Capitalization: $83.35 (millions)
|
|
|
|
|
|
EPS Information |
Dividend Information |
Analyst Coverage: No |
Dividend Yield: 0.00% |
Current Fiscal Quarter EPS Consensus Estimate: $-0.13 |
Indicated Annual Dividend: $0.00 |
Current Fiscal Year EPS Consensus Estimate: $-0.33 |
Payout Ratio: |
Number of Estimates in the Fiscal Year Consensus: 3.00 |
Change In Payout Ratio: |
Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
Next EPS Report Date: 08/11/22 |
|
|
|
|